Richard L Bennett

Prof. Richard L Bennett

Division of Hematology and Oncology, Department of Medicine, University of Florida, Gainesville, FL, USA
orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2018 in Annual Review of Pharmacology and Toxicology
Verified
Journal Article
Closed access
Richard L BennettRichard L Bennett
Richard L Bennett
JLJonathan D. Licht
Jonathan D. Licht
Alterations of genes regulating epigenetic processes are frequently found as cancer drivers and may cause widespread alterations of DNA methylation, histone modification patterns, or chromatin structure that disrupt normal patterns of gene expression. Because of the inherent reversibility of epigenetic changes, inhibitors targeting these processes are promising anticancer strategies. Small molecules targeting epigenetic regulators have been developed recently, and clinical trials of these agents are under way for hematologic malignancies and solid tumors. In this review, we describe how the writers, readers, and erasers of epigenetic marks are dysregulated in cancer and summarize the development of therapies targeting these mechanisms.

13 February 2017 in Cold Spring Harbor Perspectives in Medicine
Verified
Journal Article
Open access
PDF file
Richard L BennettRichard L Bennett
Richard L Bennett
ASAlok Swaroop
Alok Swaroop
CTCatalina Troche
Catalina Troche
JLJonathan D. D Licht
Jonathan D. D Licht
The nuclear receptor–binding SET Domain (NSD) family of histone H3 lysine 36 methyltransferases is comprised of NSD1, NSD2 (MMSET/WHSC1), and NSD3 (WHSC1L1). These enzymes recognize and catalyze methylation of histone lysine marks to regulate chromatin integrity and gene expression. The growing number of reports demonstrating that alterations or translocations of these genes fundamentally affect cell growth and differentiation leading to developmental defects illustrates the importance of this family. In addition, overexpression, gain of function somatic mutations, and translocations of NSDs are associated with human cancer and can trigger cellular transformation in model systems. Here we review the functions of NSD family members and the accumulating evidence that these proteins play key roles in tumorigenesis. Because epigenetic therapy is an important emerging anticancer strategy, understanding the function of NSD family members may lead to the development of novel therapies.

1 August 2006 in Blood
Verified
Journal Article
Open access
PDF file
Richard L BennettRichard L Bennett
Richard L Bennett
WBWilliam Blalock
William Blalock
DADean M. Abtahi
Dean M. Abtahi
YPYu Pan
Yu Pan
SMSue A. Moyer
Sue A. Moyer
WMW. Stratford May
W. Stratford May
While the interferon (IFN)–inducible double-stranded RNA (dsRNA)–dependent protein kinase PKR is reported to initiate apoptosis in some instances, the mechanism by which diverse stress stimuli activate PKR remains unknown. Now we report that RAX, the only known cellular activator for PKR, initiates PKR activation in response to a broad range of stresses including serum deprivation, cytotoxic cytokine or chemotherapy treatment, or viral infection. Thus, knock-down of RAX expression by 80% using small interfering RNA (siRNA) prevents IFNγ/tumor necrosis factor α (TNFα)–induced PKR activation and eIF2α phosphorylation, IκB degradation, IRF-1 expression, and STAT1 phosphorylation, resulting in enhanced murine embryonic fibroblast (MEF) cell survival. In contrast, expression of exogenous RAX, but not of the nonphosphorylatable, dominant-negative RAX(S18A) mutant, sensitizes cells to IFNγ/TNFα, mitomycin C (MMC), or serum deprivation in association with increased PKR activity and apoptosis. Furthermore, RAX(S18A) expression in Fanconi anemia complementation group C–null MEF cells not only prevents PKR activation but also blocks hypersensitivity to IFNγ/TNFα or mitomycin C that results in enhanced apoptosis. In addition, reduced RAX expression facilitates productive viral infection with vesicular stomatitis virus (VSV) and promotes anchorage-independent colony growth of MEF cells. Collectively, these data indicate that RAX may function as a negative regulator of growth that is required to activate PKR in response to a broad range of apoptosis-inducing stress.

1 May 2008 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
XCXuefang Cao
Xuefang Cao
Richard L BennettRichard L Bennett
Richard L Bennett
WMW. Stratford May
W. Stratford May
Activation of Bax following diverse cytotoxic stress has been shown to be an essential gateway to mitochondrial dysfunction and activation of the intrinsic apoptotic pathway characterized by cytochrome c release with caspase-9/-3 activation. Interestingly, c-Myc has been reported to promote apoptosis by destabilizing mitochondrial integrity in a Bax-dependent manner. Stress-induced activation of caspase-2 may also induce permeabilization of mitochondria with activation of the intrinsic death pathway. To test whether c-Myc and caspase-2 cooperate to activate Bax and thereby mediate intrinsic apoptosis, small interfering RNA was used to efficiently knock down the expression of c-Myc, caspase-2, and Apaf-1, an activating component in the apoptosome, in two human cancer cell lines, lung adenocarcinoma A-549 and osteosarcoma U2-OS cells. Under conditions when the expression of endogenous c-Myc, caspase-2, or Apaf-1 is reduced 80–90%, cisplatin (or etoposide)-induced apoptosis is significantly decreased. Biochemical studies reveal that the expression of c-Myc and caspase-2 is crucial for cytochrome c release from mitochondria during cytotoxic stress and that Apaf-1 is only required following cytochrome c release to activate caspases-9/-3. Although knockdown of c-Myc or caspase-2 does not affect Bax expression, caspase-2 is important for cytosolic Bax to integrate into the outer mitochondrial membrane, and c-Myc is critical for oligomerization of Bax once integrated into the membrane.

17 May 2021 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
JLJonathan D. Licht
Jonathan D. Licht
Richard L BennettRichard L Bennett
Richard L Bennett
Background: Epigenetic mechanisms regulate chromatin accessibility patterns that govern interaction of transcription machinery with genes and their cis-regulatory elements. Mutations that affect epigenetic mechanisms are common in cancer. Because epigenetic modifications are reversible many anticancer strategies targeting these mechanisms are currently under development and in clinical trials. Main body: Here we review evidence suggesting that epigenetic therapeutics can deactivate immunosuppressive gene expression or reprogram tumor cells to activate antigen presentation mechanisms. In addition, the dysregulation of epigenetic mechanisms commonly observed in cancer may alter the immunogenicity of tumor cells and effectiveness of immunotherapies. Conclusions: Therapeutics targeting epigenetic mechanisms may be helpful to counter immune evasion and improve the effectiveness of immunotherapies.

31 August 2018 in Oncogene
Verified
Journal Article
Closed access
PDF file
ASAlok Swaroop
Alok Swaroop
JOJon A. Oyer
Jon A. Oyer
CWChristine M. Will
Christine M. Will
XHXiaoxiao Huang
Xiaoxiao Huang
WYWenbo Yu
Wenbo Yu
JLJonathan D. D Licht
Jonathan D. D Licht